Canaccord Genuity cuts Ultragenyx Pharma PT to $37
Canaccord Genuity maintained a Buy rating on Ultragenyx Pharma while cutting its price target to $37.00 per share from $83.00.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.